Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade

Key Inclusion Criteria:

- Diagnosis of Immunoglobulin A nephropathy

- estimated glomerular filtration rate >60 mL/min/1.73 m2

- Proteinuria (first morning urinary protein:creatinine ratio >1g/g creatinine)

Key Exclusion Criteria:

- Severe renal disease

- Pregnant or nursing

- Proteinuria >8g/g creatinine or >8g/day

- Systemic manifestations of Henoch-Schonlein purpura within 2 years prior

- Patients with Immunoglobulin A nephropathy deemed secondary to underlying disease

- Biopsy reported severe crescentic Immunoglobulin A nephropathy

- History of treatment with glucocorticoids, cyclophosphamide, azathioprine,
mycophenolate mofetil, or any biologic immunomodulatory agent with 24 weeks prior

- History of clinically significant cardiac conditions

- History of cancer within 5 years prior

- Any infection requiring antibiotic treatment that has not cleared prior to study
start